cmp-001
mAbexperimental
Clinical trial activity
17 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
12
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02680184)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 3
- Colorectal Neoplasms · Phase 1
- Lymphoma · Phase 3
- Melanoma · Phase 2/Phase 3
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 3
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Toll-like receptor 9INHIBITOR
TLR9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315003 ↗
Also known as
- cmp-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445609 | Phase 2 | Nov 30, 2022 | Emory University, National Cancer Institute (NCI), Prostate Cancer Foundation |
| NCT04916002 | Phase 2 | Jan 31, 2022 | Checkmate Pharmaceuticals, IQVIA |
| NCT05059522 | Phase 3 | Sep 29, 2021 | Pfizer |
| NCT04807192 | Phase 2 | Apr 8, 2021 | University of Lausanne |
| NCT04708418 | Phase 2 | Mar 19, 2021 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT04698187 | Phase 2 | Feb 10, 2021 | Bristol-Myers Squibb, Regeneron |
| NCT04695977 | Phase 2/Phase 3 (Phase 3) | Feb 5, 2021 | Bristol-Myers Squibb, Regeneron |
| NCT04633278 | Phase 2 | Nov 30, 2020 | Checkmate Pharmaceuticals, IQVIA |
| NCT04401995 | Phase 2 | Jun 30, 2020 | CellSight Technologies, Inc., Checkmate Pharmaceuticals, University of Pittsburgh |
| NCT04387071 | Phase 1/Phase 2 (Phase 2) | May 15, 2020 | National Cancer Institute (NCI), University of Southern California |
| NCT03983668 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | Checkmate Pharmaceuticals, Merck, University of Iowa |
| NCT03618641 | Phase 2 | Aug 8, 2018 | Checkmate Pharmaceuticals, University of Pittsburgh |
| NCT03507699 | Phase 1 | Jul 1, 2018 | Bristol-Myers Squibb, Checkmate Pharmaceuticals, Tel Aviv University |
| NCT03438318 | Phase 1 | Mar 15, 2018 | Checkmate Pharmaceuticals, Novella Clinical |
| NCT03084640 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Checkmate Pharmaceuticals |
| NCT02680184 | Phase 1 | Mar 1, 2016 | Checkmate Pharmaceuticals, University of Iowa |
| NCT06063746 | N/A | — | Regeneron |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Checkmate Pharmaceuticals | For profit | 9 | 5 | 2 | 2016 |
| Bristol-Myers Squibb | For profit | 3 | 0 | 3 | 2018 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 1 | 2020 |
| Regeneron | For profit | 3 | 3 | 3 | 2021 |
| IQVIA | For profit | 2 | 0 | 1 | 2020 |
| University of Iowa | Academic/Hospital | 2 | 1 | 2 | 2016 |
| University of Pittsburgh | Academic/Hospital | 2 | 2 | 1 | 2018 |
| CellSight Technologies, Inc. | For profit | 1 | 0 | 1 | 2020 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| Novella Clinical | For profit | 1 | 0 | 1 | 2018 |
| Pfizer | For profit | 1 | 1 | 1 | 2021 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2020 |
17 organizations
Page 1 / 1